Literature DB >> 30417606

Sixteen years of creatinine measurements among 460 000 individuals-The Funen Laboratory Cohort (FLaC), a population-based pharmacoepidemiological resource to study drug-induced kidney disease.

Daniel Pilsgaard Henriksen1, Per Damkier1,2, Jesper Hallas1,3, Mads Nybo1,2.   

Abstract

Register-based administrative data comprise the backbone of pharmacoepidemiological research. However, information from these registers lacks biochemical details. The aim of our study was to describe the creation, coverage and content of the Funen Laboratory Cohort (FLaC). FLaC is a database comprising all inhabitants of Funen, Denmark, who in the study period of January 2000 to December 2015 had their creatinine levels measured. Data were linked to the Danish nationwide registers with information on vital status, redeemed prescriptions, discharge diagnoses, and socio-economic status. A total of 693 843 individuals lived on Funen during the study period, and we included 460 365 (66.4%) individuals with a creatinine measurement. In total, 7 742 124 creatinine measurements were performed during the study period. The coverage increased with increasing age, reaching 90%-100% of all 65-90 + year-olds in 2015. We found that an overall coverage of individuals recorded in FLaC with at least one creatinine measured redeeming prescriptions from public pharmacies was 83% (interquartile range [IQR] 75%-89%) compared to the entire Funen population. In total, 94.1% of all individuals with a discharge diagnosis of chronic kidney disease (CKD) were covered in FLaC, but only 16.5% (n = 3136) of all individuals with a laboratory-confirmed CKD also had a discharge diagnosis of CKD. We described the creation and content of the FLaC - a haven and a valuable resource for pharmacoepidemiological research using Danish nationwide administrative registers enriched with individual-level biochemical information in a population-based setting.
© 2018 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30417606     DOI: 10.1111/bcpt.13167

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  6 in total

1.  Identification of Patients with CKD in Medical Databases: A Comparison of Different Algorithms.

Authors:  Søren Viborg Vestergaard; Christian Fynbo Christiansen; Reimar Wernich Thomsen; Henrik Birn; Uffe Heide-Jørgensen
Journal:  Clin J Am Soc Nephrol       Date:  2021-03-11       Impact factor: 8.237

2.  Elevated suPAR Is an Independent Risk Marker for Incident Kidney Disease in Acute Medical Patients.

Authors:  Esben Iversen; Morten Baltzer Houlind; Thomas Kallemose; Line Jee Hartmann Rasmussen; Mads Hornum; Bo Feldt-Rasmussen; Salim S Hayek; Ove Andersen; Jesper Eugen-Olsen
Journal:  Front Cell Dev Biol       Date:  2020-06-12

3.  Kidney Disease Cohort (KidDiCo) of Southern Denmark: Design, Coverage, Generalizability and Implications for Use.

Authors:  Jan Dominik Kampmann; James Goya Heaf; Christian Backer Mogensen; Hans Mickley; Frans Brandt
Journal:  Clin Epidemiol       Date:  2021-10-14       Impact factor: 4.790

4.  Lithium and the risk of chronic kidney disease: A population-based case-control study.

Authors:  Mikkel Højlund; Jane Sterndorff Winkel; Mads Nybo; Jesper Hallas; Daniel Pilsgaard Henriksen; Per Damkier
Journal:  Basic Clin Pharmacol Toxicol       Date:  2022-06-06       Impact factor: 3.688

5.  Second-generation antipsychotics and the risk of chronic kidney disease: a population-based case-control study.

Authors:  Mikkel Højlund; Lars Christian Lund; Jonas Leander Emming Herping; Maija Bruun Haastrup; Per Damkier; Daniel Pilsgaard Henriksen
Journal:  BMJ Open       Date:  2020-08-11       Impact factor: 2.692

Review 6.  Existing Data Sources in Clinical Epidemiology: Laboratory Information System Databases in Denmark.

Authors:  Johan Frederik Håkonsen Arendt; Anette Tarp Hansen; Søren Andreas Ladefoged; Henrik Toft Sørensen; Lars Pedersen; Kasper Adelborg
Journal:  Clin Epidemiol       Date:  2020-05-18       Impact factor: 4.790

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.